7MY9

Structure of proline utilization A with 1,3-dithiolane-2-carboxylate bound in the proline dehydrogenase active site

7MY9 の概要

• エントリーDOI: 10.2210/pdb7my9/pdb
• 分子名称: Bifunctional protein PutA, 1,3-dithiolane-2-carboxylic acid, FLAVIN-ADENINE DINUCLEOTIDE, ... (10 entities in total)
• 機能のキーワード: flavoenzyme, rossmann fold, proline dehydrognease, aldehyde dehydrogenase, proline catabolism, substrate channeling, bifunctional enzyme, oxidoreductase
• 由来する生物種: Sinorhizobium meliloti (strain SM11)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 268305.43

構造登録者

Tanner, J.J.,Campbell, A.C. (登録日: 2021-05-20, 公開日: 2021-09-29, 最終更新日: 2023-10-18)

主引用文献

Campbell, A.C.,Prater, A.R.,Bogner, A.N.,Quinn, T.P.,Gates, K.S.,Becker, D.F.,Tanner, J.J.
Photoinduced Covalent Irreversible Inactivation of Proline Dehydrogenase by S-Heterocycles.
Acs Chem.Biol., 16:2268-2279, 2021

PubMed Abstract: Proline dehydrogenase (PRODH) is a flavoenzyme that catalyzes the first step of proline catabolism, the oxidation of l-proline to Δ-pyrroline-5-carboxylate. PRODH has emerged as a cancer therapy target because of its involvement in the metabolic reprogramming of cancer cells. Here, we report the discovery of a new class of PRODH inactivator, which covalently and irreversibly modifies the FAD in a light-dependent manner. Two examples, 1,3-dithiolane-2-carboxylate and tetrahydrothiophene-2-carboxylate, have been characterized using X-ray crystallography (1.52-1.85 Å resolution), absorbance spectroscopy, and enzyme kinetics. The structures reveal that in the dark, these compounds function as classical reversible, proline analogue inhibitors. However, exposure of enzyme-inhibitor cocrystals to bright white light induces decarboxylation of the inhibitor and covalent attachment of the residual S-heterocycle to the FAD N5 atom, locking the cofactor into a reduced, inactive state. Spectroscopic measurements of the inactivation process in solution confirm the requirement for light and show that blue light is preferred. Enzyme activity assays show that the rate of inactivation is enhanced by light and that the inactivation is irreversible. We also demonstrate the photosensitivity of cancer cells to one of these compounds. A possible mechanism is proposed involving photoexcitation of the FAD, while the inhibitor is noncovalently bound in the active site, followed by electron transfer, decarboxylation, and radical combination steps. Our results could lead to the development of photopharmacological drugs targeting PRODH.

PubMed: 34542291
DOI: 10.1021/acschembio.1c00427

実験手法

X-RAY DIFFRACTION (1.628 Å)